How GitLab Co-Founder Sid Sijbrandij Used ChatGPT to Beat Terminal Cancer: Full Review of the 2026 OpenAI Forum Event Replay

By Editorial Team


Published: June 9, 2026   |   Reading time: 8 minutes   |   Category: AI in Healthcare • Personalized Medicine

In late 2022, GitLab co-founder and Executive Chair Sid Sijbrandij received a terminal cancer diagnosis. Standard treatments failed. Doctors offered trials or hospice. Instead, he treated his rare high-grade osteosarcoma like a startup problem — and ChatGPT became his most powerful co-pilot.

This is the full, no-hype review of the March 18, 2026 OpenAI Forum event replay titled “From Terminal to Turnaround: How GitLab’s Co-Founder Leveraged ChatGPT in His Cancer Fight.”

🎥 Watch the full 1-hour replay here: ► OpenAI Forum Event Replay (Free & Public)

Raw, technical, and deeply human — one of the best real-world AI use cases ever shared.

The Story: From Terminal Diagnosis to “No Evidence of Disease”

After surgery, radiation, and brutal chemotherapy, Sid enjoyed two years of remission. Then the cancer returned — aggressively. No standard options remained.

Instead of accepting the prognosis, Sid stepped down from day-to-day CEO duties at GitLab, assembled a world-class “N=1” medical team, and attacked the problem with founder-mode intensity: 25 terabytes of his own data (single-cell sequencing, RNA/DNA, organoids, targeted imaging), parallel experimental therapies (personalized mRNA vaccine, logic-gated CAR-T, TCR-T, radioligand therapy in Germany), and heavy use of ChatGPT (GPT-4o Pro + custom AI agents).

Outcome: After targeted radioactive treatment and surgery, he reached “no evidence of disease.” The session ends with cautious optimism and a commitment to open-source the data at osteosarc.com.

AI-powered cancer treatment concept with ChatGPT analyzing medical data

How ChatGPT Was Used: Practical, Reproducible Examples

This is NOT hype. The talk shows exactly how they used ChatGPT:

  • Feeding CSV files of RNA sequencing data to instantly flag overlooked targets (B7H3 and PENX3 expressed at 10,000× levels)
  • Building lightweight AI agent systems for literature review, hypothesis generation, and bioinformatics — producing Python code + plots for ~$20 and 30 minutes
  • Cross-checking drug combinations organ-by-organ for side effects
  • Analyzing terabytes of personal medical data with patience no human researcher could match

Sid and geneticist Jacob Stern (who ran operations) call ChatGPT the ultimate “force multiplier” for a determined patient + expert team.

Personalized mRNA vaccine and AI in cancer immunotherapy diagram

What Makes This Event Replay Exceptional

  • Real patient agency — Shows how the medical system is built for RCTs and liability, not maximal individual survival. Sid’s team routed around bottlenecks.
  • Technical depth without jargon overload — Covers FAP-high cells, MDM2 overexpression, turning a “cold” tumor “hot,” and logic-gated CAR-T to avoid liver toxicity.
  • Honesty about the lows — Lung mets scares, inoperable moments, 4 blood transfusions, FDA single-patient IND delays.
  • Actionable blueprint — Sid and Jacob are now launching companies (Thalus for diagnostics, Arden for immune parsing) to scale this model.

Minor Critiques

  • It’s hosted on OpenAI’s forum — expect some natural enthusiasm for the technology.
  • This is an N=1 story requiring money, connections, and expertise most patients don't have. The speakers are transparent about this and focus on democratization (cheap sequencing + public data + trial reform).

Who Should Watch This Replay

  • Anyone facing (or supporting someone with) aggressive or rare cancer.
  • AI skeptics wanting grounded, high-stakes examples.
  • Doctors, researchers, and policymakers interested in the future of personalized medicine.
  • Tech founders — Sid’s “founder mode on cancer” framing is pure gold.

Final Verdict: 9.5/10

This is more than inspirational — it’s a practical blueprint showing how ChatGPT and AI can compress months of research into days when combined with rigorous data and human determination.

Watch it. Then visit osteosarc.com for the raw data and timeline.

Ready to see AI change medicine forever?

Watch the Full OpenAI Event Replay Now →

Frequently Asked Questions (FAQ)

How did Sid Sijbrandij use ChatGPT in his cancer fight? 
He used GPT-4o and custom agents to analyze RNA sequencing data, generate hypotheses, write bioinformatics code, and review literature at unprecedented speed.
 
Was ChatGPT the only tool that cured his cancer? 
No. It was a powerful accelerator alongside 25 TB of personal data, a top medical team, personalized mRNA vaccine, CAR-T therapies, and radioligand treatment.
 
Is this story relevant for other cancer patients? 
Yes — especially rare or aggressive cases. The talk emphasizes data transparency and reforms needed to make personalized AI-driven medicine accessible to more people.
 
Where can I watch the full event replay? 

Comments

Post a Comment

Popular posts from this blog

Ivermectin for Cancer Treatment: Protocols and Evidence (2026 Update)

By Editorial Team
Image
Ivermectin is a drug primarily used to treat parasitic infections, and it has attracted research interest for its potential biological effects in cancer models, particularly within integrative and experimental treatment contexts. Supporters point to hundreds of preclinical studies and case reports showing anti-tumor activity across multiple cancer types.  However, current mainstream oncology guidelines do not support ivermectin as a standard or evidence-based treatment for cancer, especially as a substitute for established therapies such as immunotherapy, targeted therapy, chemotherapy, or radiotherapy. So where does the truth lie? The answer is more nuanced than either side often suggests. Access to modern cancer care remains uneven globally. Advanced diagnostic testing, molecular profiling, and novel therapies are often more accessible in high-income healthcare systems or through comprehensive insurance coverage. In contrast, patients in lower-resource or impoverished settings m...
Read more

Fenbendazole and the Joe Tippens Protocol: Evidence, Risks, and Current Perspective (2026 Update)

By Editorial Team
Image
Introduction The Joe Tippens Protocol revolves around the off-label use of fenbendazole (a veterinary dewormer commonly sold as Panacur C or Safe-Guard) combined with various supplements for cancer. The Protocol has been gaining rapid interest over the past years following some  fenbendazole advanced cancer success stories . Joe Tippens popularized this approach after claiming it contributed to his remission from metastatic small-cell lung cancer in 2017. As of 2026, Joe Tippens remains alive and reports being cancer-free for over 8 years, continuing a maintenance version of the protocol. Fenbendazole is marketed for animals (e.g., Panacur C, Safe-Guard ) and has no regulatory approval for human cancer treatment . Evidence for anticancer effects is primarily preclinical or anecdotal , and clinical trials in humans are lacking. Important Disclaimer: Fenbendazole is not approved by the FDA, EMA, or any regulatory body for human use or canc...
Read more

Fenbendazole and Ivermectin for Cancer: A Case Series of Over 700 Patients (2026)

By Editorial Team
Image
Medically Reviewed by: OneDayMD Editorial Team | Last Updated: May 2026 Anecdotal reports and preliminary studies suggest that ivermectin and fenbendazole, both antiparasitic drugs, may have potential anticancer effects when used alongside other treatments.  Many people immediately dismiss the potential of ivermectin and fenbendazole when they learn it is “horse or dog medicine”. That initial reaction is overcome when genuine human success stories are told including the lack of serious side effects. The testimonials you are about to read are from individuals who have bravely shared their experiences in the hope of inspiring and uplifting others. These are raw human accounts, unfiltered by gatekeepers—not peer-reviewed studies—but they offer insights that may be valuable to those searching for options. However, we acknowledge that robust clinical trials are needed to provide more conclusive scientific evidence. Table of Contents: Editor's Preface Introduction Fenbendazole and Iverme...
Read more

Top 10 Cancer Fighting Supplements: Evidence Based Literature Review (2026 Update)

By Editorial Team
Image
Are you overwhelmed by conflicting advice on cancer, diet, and supplements ? You’re not alone. With so many claims out there, it’s hard to separate fact from fiction . Can certain foods lower your cancer risk ? Are some foods increasing it without you realizing? What about vitamin and mineral supplements —do they help prevent cancer, or could they actually increase your risk ? The term " anti-cancer supplements " can be misleading. While some nutrients support the body in cancer prevention or treatment, others may interfere with therapies or even pose risks. There are presently over 1,500 herbs and food supplements in commerce, many of them with claims in use against cancer. This guide compiles over 500 scientific r...
Read more

Fact Check: Can Ivermectin and Fenbendazole Help Treat Cancer?

By Editorial Team
Image
Ivermectin and fenbendazole, originally developed as antiparasitic drugs, are sparking hope in the fight against cancer, fueled by inspiring stories like those shared by actor  Mel Gibson on The Joe Rogan Experience , where he celebrated friends’ remarkable recoveries. While these medications aren’t yet standard cancer treatments, early research is uncovering exciting potential. Scientists are encouraged by promising lab studies and are calling for more clinical trials to confirm their effectiveness and ensure safe use in humans, paving the way for innovative, accessible therapies that could transform lives. Introduction and Context According to a January 22, 2025 fact-check article by AFP: "The anti-parasitic drugs ivermectin and fenbendazole are not currently recommended for cancer, but posts spread across social media touting the medications after actor  Mel Gibson claimed on the Joe Rogan Experience  that they cured his friends' cases of the disease. Oncology ex...
Read more

Exploring Ivermectin, Mebendazole and Fenbendazole as Aggressive Cancer Treatments: Research, Protocols, and Controversies (2026)

By Editorial Team
Image
Fenbendazole and ivermectin, both antiparasitic drugs that have shown potential in cancer treatment through several mechanisms, such as slowing cancer cell growth and boosting the immune response. Fenbendazole is being studied for its ability to disrupt energy production in cancer cells, effectively hindering their growth. Ivermectin, on the other hand, has been explored in combination with checkpoint inhibitors to boost the immune system's response to tumors—especially in challenging cases like triple-negative breast cancer. Introduction Cancer remains a leading cause of morbidity and mortality worldwide, with an increasing incidence of aggressive and treatment-resistant tumors such as triple-negative breast cancer (TNBC), pancreatic adenocarcinoma, and glioblastoma. Despite significant advances in targeted therapies and immunotherapies, many patients continue to face limited effective options, highlighting an urgent need for novel, affordable, and accessible treatment strategies....
Read more

Fenbendazole and Cancer: What the Science Really Shows (Evidence, Risks & Open Questions)

By Editorial Team
Image
Abstract Background:  Fenbendazole (FBZ), a benzimidazole anthelmintic approved for veterinary use, has attracted attention for potential anticancer activity based on laboratory findings and widespread anecdotal reports.  Objective:  To critically appraise the current evidence on fenbendazole and cancer using a peer‑review style framework.  Methods:  Narrative review of preclinical studies, publicly reported human case narratives, and safety signals, with emphasis on evidence hierarchy and translational limitations.  Results:  Preclinical data demonstrate antiproliferative effects via microtubule disruption and metabolic stress in vitro and in animal models. Human evidence is limited to uncontrolled case reports; no Phase I–III clinical trials or regulatory approvals for oncology exist. Safety data in humans are sparse, with hepatotoxicity signals reported.  Conclusions:  Fenben...
Read more

Fenbendazole vs Ivermectin for Cancer: Differences and Which Is Better?

By Editorial Team
Image
Cancer patients are increasingly inquiring about the use of the anthelmintic drugs Fenbendazole (FenBen) and Ivermectin (IVM) as potential treatments for cancer. Notably, these patients typically fall into two distinct groups, neither of which represents the usual stage 1 or 2 cancer cases where conventional therapies often show promise. The first group consists of older men whose lung or prostate cancer has recurred. Having undergone conventional treatments previously without success, they express skepticism about its effectiveness this time around. The second, larger group comprises younger patients under 40 dealing with aggressive breast cancer, colorectal cancer, or lymphoma—forms of early-onset cancers that appear to lack the typical mutations observed in traditional cases. This article aims to delve into the differences between Fenbendazole and Ivermectin by examining their me...
Read more

Dr. William Makis's Recommended Ivermectin Dosages for Cancer (2026)

By Editorial Team
Image
Dr. William Makis, a radiologist and cancer researcher, has developed a "hybrid orthomolecular" protocol that incorporates ivermectin as a repurposed drug for cancer treatment. This approach targets cancer stem cells and mitochondrial dysfunction, often in combination with other therapies like benzimidazoles (e.g., mebendazole or fenbendazole), vitamins, and dietary changes. The protocol is based on preclinical studies, case reports, and his clinical observations, but it remains experimental and unapproved by regulatory bodies like the FDA for cancer use. Dosages are weight-based (e.g., for a 70 kg/154 lb person, 1 mg/kg = 70 mg) and stratified by cancer severity: low-grade (early-stage or slow-growing), intermediate-grade (moderately progressive), or high-grade (aggressive, metastatic, or "turbo" cancers). Always consult a healthcare provider for personalization, monitoring (e.g., liver/kidney function), and integration with conventional treatments. Key Ivermectin...
Read more

Fenbendazole and Ivermectin for Stage 4 Pancreatic Cancer: A Compilation of Case Reports and Mechanistic Insights (2026)

By Editorial Team
Image
Summary Background: Pancreatic ductal adenocarcinoma (PDAC) remains one of the most lethal malignancies, with limited effective therapies and poor survival, especially in stage 4 disease. Repurposing antiparasitic agents such as fenbendazole and ivermectin has garnered interest due to their demonstrated anti-cancer properties in preclinical studies. Methods: We reviewed and synthesized 35 detailed case reports from 2022 to 2026 documenting the clinical use of fenbendazole and ivermectin, alone or in combination with standard therapies, in patients with advanced pancreatic cancer. Tumor markers, imaging outcomes, and clinical responses were analyzed alongside mechanistic literature. Results: Across cases, patients exhibited marked reductions in CA19-9 tumor markers (often >70%), significant tumor shrinkage on imaging, and improved clinical status. Responses were observed even in chemotherapy-resistant and metastatic disease. Mechanistic studies support multiple anti-cancer effects of...
Read more

Archive

Show more